certificate of analysis comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-08-01. Numbers and descriptions here follow the published literature rather than marketing material.
Physicochemical behavior influences handling. SR9009 is described as a solid with limited aqueous solubility, so organic solvents such as dimethyl sulfoxide or ethanol are common in research stock solutions. Aqueous dilution can produce precipitates if the organic content is too low. Light, heat, and repeated freeze-thaw cycles may affect stability. Storage recommendations usually specify a desiccated freezer environment protected from light, but exact stability data depend on the formulation and matrix.
Detection in biological samples can be complicated by rapid metabolism and low circulating concentrations. Some studies report phase I and phase II metabolites, and analytical methods may need to target those species in addition to the parent compound. Immunoassays are not broadly available, so mass spectrometry remains the main confirmatory approach. For anti-doping testing, laboratories look for SR9009 and its metabolites using validated LC-MS methods. Open questions include how long metabolites remain detectable and how different routes of administration alter detection windows.
In laboratory settings, SR9009 is typically characterized by liquid chromatography–mass spectrometry (LC-MS) or high-performance liquid chromatography with ultraviolet detection (HPLC-UV). These methods can confirm identity and estimate purity, but they require reference standards for accurate quantification. Because SR9009 is not a licensed pharmaceutical, no harmonized pharmacopeial monograph exists. Laboratories often validate in-house methods for matrices such as plasma, urine, or cell culture media. Sample preparation may involve protein precipitation or liquid-liquid extraction before analysis.
SR9009 is often grouped with compounds studied for circadian and metabolic regulation rather than with classical anabolic steroids. Its interactions with nuclear receptors differ from those of androgen receptor ligands, and its proposed mechanisms involve transcriptional control rather than direct hormone signaling. Some sources classify it as a metabolic modulator because of observed effects on energy utilization. The distinction matters for regulation and for interpreting research results across different compound classes.
SR9009 is a synthetic small molecule developed as a REV-ERB agonist. It binds to REV-ERBα and REV-ERBβ, nuclear receptors that help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, the compound alters lipid and glucose handling and influences skeletal muscle oxidative capacity. Its exact effects in humans remain largely uncharacterized because controlled clinical trials have not been reported. The molecule is frequently described in preclinical literature as a metabolic modulator.
Research interest in SR9009 grew from studies showing improved running endurance in mice after short treatment periods. Those experiments linked the compound to increased mitochondrial content and fatty acid oxidation in muscle, but the findings come from animal models and specific dosing schedules. Independent replication has been limited, and the pathways connecting REV-ERB activation to exercise performance are still being mapped. Whether similar responses occur in humans is an open question.
| Property | Value | Notes |
|---|---|---|
| Appearance | Off-white to pale yellow solid | Visual description varies with purity and source |
| Solubility | Soluble in DMSO and ethanol; poorly soluble in water | Organic stock solutions are common in research |
| Typical storage | -20 °C, desiccated, protected from light | Avoid repeated freeze-thaw cycles |
| Typical analytical method | LC-MS or HPLC-UV | Reference standards are needed for quantification |
| Molar mass | Approximately 437.9 g/mol | Calculated from the reported free-base formula |
Storage conditions for research-grade SR9009 generally involve a freezer at approximately minus twenty degrees Celsius, sometimes lower for long-term preservation. Containers should remain tightly closed and protected from light. Desiccants may be used to limit moisture uptake. Solutions are often stored in aliquots to avoid repeated warming and cooling. Stability data for the compound under various conditions are limited, so laboratories typically follow supplier recommendations and verify performance through periodic analytical checks rather than assuming indefinite stability.
Identity and purity testing for SR9009 commonly uses liquid chromatography coupled with tandem mass spectrometry. This method separates the compound from matrix components and detects it by mass-to-charge transitions, providing sensitive and specific confirmation. Nuclear magnetic resonance spectroscopy can support structural identification, while high-performance liquid chromatography with ultraviolet detection may estimate purity. Because online products labeled as SR9009 may contain other substances or no active compound at all, independent verification is important in research settings. Certificates of analysis are useful but not a substitute for in-house testing.
SR9009 is supplied as a solid research chemical, often in milligram quantities. Laboratories typically weigh it in a controlled environment because fine powders can disperse. Stock solutions are commonly prepared in dimethyl sulfoxide and stored in small aliquots to reduce freeze-thaw cycles. Personal protective equipment and chemical fume hoods are standard when handling unknown or potent compounds. These practices address laboratory safety rather than human use.
Identity and purity of SR9009 samples are usually checked with chromatographic and spectrometric methods. High-performance liquid chromatography can separate the compound from related impurities, while mass spectrometry provides molecular mass confirmation. Nuclear magnetic resonance spectroscopy may be used for structural verification in research settings. No single method proves biological activity, and certificates of analysis should be reviewed alongside raw data. Independent testing is often needed because online products vary widely.
REV-ERB proteins help regulate daily cycles in gene expression, including genes tied to lipid and glucose metabolism. SR9009 binds these receptors and alters their activity in cell and animal experiments. Consequences observed in rodents include changes in skeletal muscle oxidative capacity, blood lipid levels, and exercise performance. The precise chain from receptor occupancy to whole-body effects is still an active area of study. Human responses cannot be assumed from rodent data.
Most published work on SR9009 consists of preclinical studies. It is widely sold as a research chemical, a category that does not imply safety, efficacy, or pharmaceutical-grade quality. Sports anti-doping organizations have listed SR9009 as a prohibited substance, and its presence in an athlete sample can lead to sanctions. Legal status differs by country; in several jurisdictions it is not approved for human consumption and may be treated as an unapproved new drug.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not a steroid, peptide, or natural hormone. In scientific literature, it appears under the code SR9009 and in non-scientific contexts as Stenabolic. The compound was identified through chemical screening efforts aimed at targeting circadian clock components. Its status remains investigational, and no regulatory agency has approved it as a human medicine.
production of the drug(s) or device(s) being evaluated staff salaries for the designers and administrators of the trial payments to the contract research organization, the site management organization (if used) and any outside consultants payments to local researchers and their staff for their time and effort in recruiting test subjects and collecting data for the sponsor the cost of study materials and the charges incurred to ship them communication with the local researchers, including on-site monitoring by the CRO before and (in some cases) multiple times during the study one or more investigator training meetings expense incurred by the local researchers, such as pharmacy fees, IRB fees and postage any payments to subjects enrolled in the trial the expense of treating a test subject who develops a medical condition caused by the study drug These expenses are incurred over several years. In the US, sponsors may receive a 50 percent tax credit for clinical trials conducted on drugs being developed for the treatment of orphan diseases. National health agencies, such as the US National Institutes of Health, offer grants to investigators who design clinical trials that attempt to answer research questions of interest to the agency. In these cases, the investigator who writes the grant and administers the study acts as the sponsor, and coordinates data collection from any other sites. These other sites may or may not be paid for participating in the study, depending on the amount of the grant and the amount of effort expected from them.
=== Brand names === In France, Portugal and Spain it is sold as Tiorfan and in Italy as Tiorfix, in Czechia and Slovakia as Enditril. In India it is available as Redotril and Enuff. In the Philippines it is sold as Hidrasec.
Some drugs have the capacity to bind with certain types of proteins that are carried in blood plasma. This is important as only drugs that are present in the plasma in their free form can be transported to the tissues. Drugs that are bound to plasma proteins therefore act as a reservoir of the drug within the organism and this binding reduces the drug's final concentration in the tissues. The binding between a drug and plasma protein is rarely specific and is usually labile and reversible. The binding generally involves ionic bonds, hydrogen bonds, Van der Waals forces and, less often, covalent bonds. This means that the bond between a drug and a protein can be broken and the drug can be replaced by another substance (or another drug) and that, regardless of this, the protein binding is subject to saturation. An equilibrium also exists between the free drug in the blood plasma and that bound to proteins, meaning that the proportion of the drug bound to plasma proteins will be stable, independent of its total concentration in the plasma. In vitro studies carried out under optimum conditions have shown that the equilibrium between a drug's plasmatic concentration and its tissue concentration is only significantly altered at binding rates to plasma proteins of greater than 90%. Above these levels the drug is "sequestered", which decreases its presence in tissues by up to 50%.
== Strong acids and bases == An acid is classified as "strong" when the concentration of its undissociated species is too low to be measured. Any aqueous acid with a pKa value of less than 0 is almost completely deprotonated and is considered a strong acid. All such acids transfer their protons to water and form the solvent cation species (H3O+ in aqueous solution) so that they all have essentially the same acidity, a phenomenon known as solvent leveling. They are said to be fully dissociated in aqueous solution because the amount of undissociated acid, in equilibrium with the dissociation products, is below the detection limit. Likewise, any aqueous base with an association constant pKb less than about 0, corresponding to pKa greater than about 14, is leveled to OH− and is considered a strong base. Nitric acid, with a pK value of around −1.7, behaves as a strong acid in aqueous solutions with a pH greater than 1. At lower pH values it behaves as a weak acid. pKa values for strong acids have been estimated by theoretical means. For example, the pKa value of aqueous HCl has been estimated as −9.3.
(1999), "Conditioned Arising Evolves: Variation and Change in Textual Accounts of the Paticca-samupadda Doctrine", Journal of the International Association of Buddhist Studies, 22 (2) Jurewicz, Joanna (2000), "Playing with Fire: The pratityasamutpada from the perspective of Vedic thought", Journal of the Pali Text Society, 26: 77–103 Shulman, Eviatar (2008), "Early Meanings of Dependent-Origination" (PDF), Journal of Indian Philosophy, 36 (2): 297–317, doi:10.1007/s10781-007-9030-8, S2CID 59132368, archived from the original (PDF) on 10 October 2016 Gombrich, Richard (2009), "Chaper 9. Causation and non-random process", What the Buddha Thought, Equinox Jones, Dhivan Thomas (2009), "New Light on the Twelve Nidanas", Contemporary Buddhism, 10 (2): 241–259, doi:10.1080/14639940903239793, S2CID 145413087
Sources: en.wikipedia.org
=== Autoimmunity treatment === Acting as DAMPs, HSPs can extracellularly promote autoimmune reactions leading to diseases as rheumatoid arthritis or systemic lupus erythematosus. Nevertheless, it was found, that application of some HSPs into patients is able to induce immune tolerance and treat autoimmune diseases. The underlying mechanism is not known. HSPs (especially hsp60 and hsp70) are used in clinical studies to treat rheumatoid arthritis and type 1 diabetes. Current therapeutic research areas in the treatment for DM include: long-term physical exercise, hot tub therapy (HTT), and alfalfa-derived HSP70 (aHSP70). Hsp90 inhibitors are another possible treatment for autoimmunity, because hsp90 is necessary for proper folding of many pro-inflammatory proteins (components of PI3K, MAPK and NF-kB cascades).
The county is named after the ancient Welsh Kingdom of Powys, which in the sixth century AD included the northern two-thirds of the area as well as most of Shropshire, Herefordshire and adjacent areas now in England, and came to an end when it was occupied by Llywelyn ap Gruffudd of Gwynedd during the 1260s. The uplands retain evidence of occupation from long before the Kingdom of Powys, and before the Romans, who built roads and forts across the area. There are 1130 identified burial mounds within the county, of varying styles and ages, dating from 4000 BC to 1000 BC, most of them belonging to the Bronze Age. Of these, 339 are scheduled monuments. Standing stones, most again dating to the Bronze Age, also occur in large numbers, 276 being found across the county, of which 92 are scheduled. From the Iron Age, the county has 90 scheduled hillforts and a further 54 enclosures and settlement sites. Powys is served by the Cambrian Line and Heart of Wales line which offer connections to major towns and cities such as Swansea, Wrexham, Shrewsbury, Birmingham, Wolverhampton, Manchester, Cardiff, Aberystwyth, London and Telford. The county used to be served by key railways such as the Mid-Wales Railway, Oswestry and Newtown Railway, Tanat Valley Light Railway, Llanfyllin Branch, Leominster and Kington Railway, Swansea Vale Railway and the Hereford, Hay and Brecon Railway, all of which offered connections to South Wales, Hereford, Oswestry, North Wales and West Wales but have all since closed.
After a memorable 90th birthday, at which she was surrounded by her now vast family, Zita's habitually-robust health began to fail. She developed inoperable cataracts in both eyes. Her last major family gathering took place at Zizers, in 1987, when her children and grandchildren joined in celebrating her 95th birthday. While visiting her daughter, in summer 1988, she developed pneumonia and spent most of the autumn and winter bedridden. Finally, she called Otto in early March 1989 and told him she was dying. He and the rest of the family travelled to her bedside and took turns keeping her company until she died in the early hours of 14 March 1989. She was 96 years old, and was the last surviving child of Robert, Duke of Parma from both his marriages. Her funeral was held in Vienna on 1 April. The government allowed it to take place on Austrian soil if the cost was borne by the Habsburgs themselves. Zita's body was carried to the Imperial Crypt under Capuchin Church in the same funeral coach she had walked behind during the funeral of Emperor Franz Joseph in 1916. It was attended by over 200 members of the Habsburg and Bourbon-Parma families, and the service had 6,000 attendees including leading politicians, state officials and international representatives, including a representative of Pope John Paul II. Following an ancient custom, the Empress had asked that her heart, which was placed in an urn, stay behind at Muri Abbey, in Switzerland, where the Emperor's heart had rested for decades.
Antioxidants − Many antioxidants are used in food industry as food additives. These compounds react with oxygen and suppress the initiation of the browning process. Also, they interfere with intermediate products of the following reactions and inhibit melanin formation. Ascorbic acid, N-acetylcysteine, L-cysteine, 4-hexylresorcinol, erythorbic acid, cysteine hydrochloride, glutathione are examples of antioxidants that have been studied for their anti-browning properties. Chelating agents − Polyphenol oxidase requires copper as a cofactor for its functionality, thus copper-chelating agents inhibit the activity of this enzyme. Many agents possessing chelating activity have been studied and used in different fields of food industry, such as citric acid, sorbic acid, polyphosphates, hinokitiol, kojic acid, EDTA, porphyrins, polycarboxylic acids, different proteins. Some of these compounds also have other anti-browning effects, such as acidifying or antioxidant. Hinokitiol is used in coating materials for food packaging.
Sources: en.wikipedia.org
=== Phytochemistry === Natural tobacco polysaccharides, including cellulose, have been shown to be the primary precursors of acetaldehyde in tobacco smoke. The main polyphenols contained in the tobacco leaf are rutin and chlorogenic acid. Amino acids contained include glutamic acids, asparagine, glutamine, and γ-Aminobutyric acid. Pyridine alkaloids are present in tobacco as free bases and salts. Nicotine accounts for 90–95% of the plant's pyridines with nornicotine and anatabine accounting for roughly 2.5% each. Pyridyl functional groups present in minute amounts include anabasine, myosmine, cotinine and 2, 3′-bipyridyl. Indole alkaloids are also present in leaves and stems which includes harmala alkaloids as well. Yohimbine, harmine, harmaline and ajmalicine occurs in descending order, yohimbine being highest. The tobacco plant readily absorbs heavy metals from the surrounding soil and accumulates them in its leaves. These are readily absorbed into the user's body following smoke inhalation. Tobacco also contains the following phytochemicals: glucosides (tabacinine, tabacine), 2,3,6-trimethyl-1,4-naphthoquinone, 2-methylquinone, 2-Naphthylamine, propionic acid, anthalin, anethole, acrolein, cembrene, choline, nicotelline, nicotianine, and pyrene.
== Pharmacokinetics == Lamivudine is well absorbed in the body and distributes widely into the extravascular space. Oral bioavailability is >80% and overall metabolism is insignificant where approximately 95% of the drug is found unchanged in the urine. The only known metabolite found in humans is trans-sulfoxide. The half-life of lamivudine is 10 to 15 hours and binds poorly to plasma proteins. Zidovudine is also well absorbed in the body and penetrates into the cerebrospinal fluid. Oral bioavailability is 75% and primarily metabolized by the liver by glucuronidation. The primary metabolite is GZDV, an inactive metabolite produced after first pass metabolism. The half-life of zidovudine is 0.5 to 3 hours and binds poorly to plasma proteins. Lamivudine and zidovudine are not extensively metabolized by CYP450 liver enzymes.
Suvorexant is approved for the treatment of insomnia by the United States Food and Drug Administration (FDA) at doses of 5 to 20 mg and by the Australian Therapeutic Goods Administration (TGA) and Japanese Pharmaceuticals and Medical Devices Agency (PMDA) at doses of 15 mg (in the elderly) and 20 mg (in younger adults). In the United States, the recommended starting dose is 10 mg and the maximum recommended dose is 20 mg. Higher doses of 30 and 40 mg were also submitted to regulatory agencies for approval but were not authorized due to lack of clearly superior efficacy to doses of 15 to 20 mg and concerns about next-day effects and associated impairment (e.g., driving). In addition to the preceding doses, suvorexant has been assessed at higher doses of up to 100 mg in clinical trials. These higher doses appeared to be more effective at promoting sleep than lower doses but produced greater next-day effects. Lower approved doses of suvorexant in the United States in the range of 5 to 10 mg were not extensively evaluated in clinical trials. The American Academy of Sleep Medicine's 2017 clinical practice guidelines recommend the use of suvorexant in the treatment of sleep-onset and sleep-maintenance insomnia along with various other sleep medications. Orexin receptor antagonists are not used as first-line treatments for insomnia due to their costs and concerns about possible misuse liability. Generic formulations of orexin receptor antagonists including suvorexant are not yet available.
Sources: en.wikipedia.org
It is usually detected by LC-MS or HPLC-UV against a reference standard. In biological matrices, metabolite targeting can improve detection. No universal immunoassay is widely available.
The compound is generally handled as light-sensitive and stored cold and dry. Stability in solution depends on solvent, concentration, and storage time. Specific degradation rates are not fully standardized.
Limited water solubility affects formulation for cell and animal studies. Organic co-solvents are often used to dissolve it. Precipitation can confound assay results if not controlled.
It is a synthetic REV-ERB agonist used mainly in preclinical research. It is not an approved medicine for human use.